High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples